Vaccines & Lymphoma — what's safe during & after treatment

As a general rule, inactivated (non-live) vaccines are safe during lymphoma treatment — for example the inactivated flu vaccine, most COVID-19 vaccines, and pneumococcal vaccines. Live vaccines are usually avoided while the immune system is suppressed by chemotherapy, antibody therapy or steroids, because a weakened live organism can occasionally cause illness in an immunocompromised person. The catch with any vaccine during treatment is that the immune response may be blunted, so timing matters. NCCN and ESMO supportive-care guidance both stress that vaccination decisions should be individualised. Always confirm the plan with your treating team before any injection — speak to your CION oncologist during lymphoma treatment.

Yes — the inactivated flu vaccine (the injection, not the live nasal spray) is recommended for most people receiving chemotherapy, because influenza can be far more serious for someone whose immune defences are low. The response may be weaker than in a healthy person, so many teams try to time the flu vaccine between chemotherapy cycles, ideally when blood counts have recovered, to give the best chance of a good response. Household members and close contacts should also be vaccinated to create a protective ring around you. The live nasal-spray flu vaccine is avoided during and shortly after treatment. Your CION team will advise the best timing around your regimen and can coordinate this with low-blood-count monitoring.

For most vaccinations after lymphoma treatment, teams commonly wait until the immune system has had time to recover — often around 3 to 6 months after finishing chemotherapy for inactivated vaccines, and longer for live vaccines. If you received an anti-CD20 monoclonal antibody, the B-cells it depletes can take many months to return, so vaccine responses may stay blunted and teams often wait around 6 months after the last dose before revaccinating. After a stem-cell transplant (coordinated through an accredited partner centre) a full re-vaccination schedule is usually needed because prior immunity is lost. The exact timing is individual — your CION oncologist will map it to your treatment. See also life after lymphoma treatment.

Live vaccines contain a weakened form of a virus or bacterium. In a healthy person the immune system controls it easily and builds protection. But when lymphoma or its treatment has suppressed the immune system, that weakened organism can occasionally multiply and cause the very infection the vaccine is meant to prevent. For this reason, live vaccines — such as the MMR, chickenpox (varicella), live nasal-spray flu and yellow fever vaccines — are generally avoided during treatment and for a period afterwards until immune recovery is confirmed. Inactivated vaccines carry no such risk and are preferred. If travel or exposure raises the question of a live vaccine, discuss it well in advance with your CION team so timing and alternatives can be planned.

Yes — this is one of the most useful protective steps. When people around you are vaccinated, they are far less likely to catch and pass on infections, creating a protective ring (sometimes called cocooning) around someone whose own immunity is low. Household members and close contacts should stay up to date with the inactivated flu vaccine and COVID-19 vaccine in particular. One nuance: if a household member receives a live vaccine, occasional simple precautions may be advised for a short period — for example around the rotavirus vaccine in an infant — so mention it to your team. Protecting the people around you complements the infection-prevention steps you take yourself.

They can still help, but the protection may be weaker or shorter-lived than in someone with a healthy immune system. Chemotherapy, steroids and especially anti-CD20 antibody therapy (which depletes the B-cells that make antibodies) can blunt the response to a vaccine. That does not make vaccination pointless — some protection is better than none, and it is why timing matters: teams try to vaccinate when counts have recovered and, where possible, before or well after B-cell-depleting therapy. After treatment, some vaccines may need to be repeated once immunity has recovered. Your CION oncologist will judge the best window for each vaccine and, for post-transplant patients, arrange a structured re-vaccination schedule.

Generally yes. People with lymphoma are at higher risk of serious infection, so COVID-19 vaccination and pneumococcal (pneumonia) vaccination are usually recommended — these are inactivated or non-live and are considered safe during treatment. Because the immune response may be reduced, additional or booster doses are sometimes advised for immunocompromised patients, and timing around chemotherapy cycles and antibody therapy is planned to improve the response. Many teams also recommend the inactivated shingles (herpes zoster) vaccine for eligible patients, as shingles is more common after lymphoma treatment. The specifics depend on your regimen and local guidance, so confirm the schedule with your CION oncologist rather than assuming — and book a consultation to plan it.